ESID COVID-19 Statement, March 2022
Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges.
IPOPI – ESID Joint Statement: The use of monoclonal antibody treatment for patients with PID in the context of the COVID-19 pandemicIPOPI ESID Statement IPOPI – ESID Joint Statement The use of monoclonal antibody treatment for patients with PID in the context of the COVID-19 pandemic 11 November 2021 The role of monoclonal antibody (mAb or moAb) therapies in the treatme...
Joint statement on the current epidemics of new Coronavirus
Together with IPOPI, INGID, APSID, ASID, ARAPID, CIS, LASID, SEAPID we have worked on a joint statement to provide guidance in advising patients with primary immunodeficiency under our care in the current COVID-19 context.
Oct 2021: Updates on registries and collaborative studies in COVID and PID
Date: Wednesday 27th October
Time: 14:00 CEST
Independent study:SARS-CoV-2 infection in patients with GATA2 deficiency
Dear ESID Member,
We and ESID Board want to pay your immediate attention to an ongoing independent survey by the COVID Human Genetic Effort on the clinical characteristics of SARS-CoV-2 infection in patients with GATA2 deficiency.
We consider this an important and timely survey. If your center has such patients, please consider, whether your center could participate in it.
Independent Survey: SARS-CoV-2 infection in patients with IRAK-4 or MyD88 deficienciesDear ESID Member, We at ESID Board want to pay your immediate attention to an ongoing independent survey by the COVID Human Genetic Effort on the clinical characteristics of SARS-CoV-2 infection in patients with IRAK-4 or MyD88 deficiencies. We...
May 2021: Managing COVID in patients with Type 1 IFN pathway defects
Date: Tuesday 18th May
Time: 17:30-18:30 CET